Etanercept therapy in patients with autoimmunity and hepatitis C

References

• Gottlieb AB, Psoriatic arthritis: A guide for dermatology nurses. Derm Nursing (2003) 15: 107–18.
   Google Scholar
• Gottlieb AB, Matheson RT, Low N et al, Randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol (2003) in press.
   Google Scholar
• Mease PJ, Goffe BS, Metz J et al, Etanercept in the treatment of psoriatic arthritis and psoriasis: a rando- mised trial. Lancet (2000) 356: 385–90.
   PubMed Web of Science ®Google Scholar
• Faulds JBD, Etanercept: a review of its use in rheumatoid arthritis. Drugs (1999) 57: 945–66.
   Google Scholar
• Gorman JD, Sack KE, Davis Jr JC, Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. NEJM (2002) 346: 1349–56.
   PubMed Web of Science ®Google Scholar
• Ettehadi P, Greaves MW, Wallach D et al, Elevated tumor necrosis factor-alpha (TNF-alpha)biological activity in psoriatic skin lesions. Clin Exp Immunol (1994) 96: 146–51.
   PubMed Web of Science ®Google Scholar
• Fabrizio C, Niccoli L, Salvarani C et al, Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum (2001) 44: 2933–5.
   Google Scholar
• Gottlieb AB, Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol (2003) in press.
   Google Scholar
• Braun J, Brandt J, Listing J et al, Treatment of active ankylosing spondylitis with inflximimab: a randomised controlled multicenter trial. Lancet (2002) 359: 1187–93.
   PubMed Web of Science ®Google Scholar
• Baert FJ, D’Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Tumor necrosis factor alpha antibody (inflixi- mab) therapy profoundly down-regulates the inflamma- tion in Crohn’s ileocolitis. Gastroenterology (1999) 116: 22–8.
   PubMed Web of Science ®Google Scholar
• Baeten D, Demetter PKruithof E et al, Effect of tumor necrosis factor-alpha blockade on synovial histology in spondyloarthropathy. Arthr Rheum (2000) 43 (suppl):2022.
   Google Scholar
• Cambell S, Ghosh S, Infliximab therapy for Crohn’s disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol (2001) 13: 191–2.
   Google Scholar
• Chaudhari U, Romano P, Mulcahy LD et al, Efficacy and safety of infliximab monotherapy for plaque-type psor- iasis: a randomised trial. Lancet (2001) 357: 1842–7.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Masud S, Ramamurthi R et al, Pharmaco- dynamic and pharmacokinetic response to anti-tumor necrosis factor monoclonal antibody (Infliximab) treat- ment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol (2002) 48: 68–75.
   Google Scholar
• Gottlieb AB, Clinical research helps elucidate the role of tumor necrosis factor-alpha (TNF-alpha) in the patho- genesis of T1 mediated immune disorders: use of targeted immunotherapeutics as pathogenic probes. Lupus (2003) 12: 192–6.
   Google Scholar
• Martinez F, Nos P, Benlloch S, Ponce J, Hidradenitis suppurativa and Crohn’s disease: response to treatment with infliximab. Inflammatory Bowel Disease (2001) 7: 323–6.
   PubMed Web of Science ®Google Scholar
• Maini RN, Breedveld FC, Kalden JR et al, Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor-alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis and Rheumatism (1998) 41: 1552– 63.
   PubMed Web of Science ®Google Scholar
• Maini R, St.Clair EW, Breedveld F et al, Infliximab (chimeric anti-tumor necrosis factor-alpha monoclonal antibody) versus placebo in theumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet (1999) 354: 1932–39.
   PubMed Web of Science ®Google Scholar
• Mussi A, Bonifati C, Carducci M et al, Serum TNF-alpha levels correlate with disease severity and are reduced by the effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents (1997) 11: 115–8.
   PubMed Web of Science ®Google Scholar
• Nikolaus S, Kuhbacher T, Foelsch UR et al, Increased peripheral production of TNF-alpha and mucosal levels of activated NFkappaB predict relapse after treatment with infliximab in patients with Crohn’s disease. Gastroenterology (2000)118 (suppl 2):2966.
   Google Scholar
• O’Quinn RP, Miller JL, The effectiveness of tumor necrosis factor alpha antibody (Infliximab) in treating recalcitrant psoriasis: a report of two cases. Arch Dermatol (2002) 138: 644–8.
   Google Scholar
• O’Shea JJ, Lipsky P, Cytokines and autoimmunity. Nature Reviews/Immunology (2002) 2: 37–45.
   Google Scholar
• Oh CJ, Das KM, Gottlieb AB, Treatment with anti-tumor necrosis factor-alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol (2000) 42: 829–30.
   PubMed Web of Science ®Google Scholar
• Piguet P, Grau GE, Allet B, Vassalli P, Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs-host disease. J Exp Med (1987) 166: 1280–9.
   PubMed Web of Science ®Google Scholar
• Present DH, Rutgeerts P, Targan S et al, Infliximab for the treatment of fistulas in patients with Crohn’s disease. NEJM (1999) 340: 1398–1401.
   PubMed Web of Science ®Google Scholar
• Van Deventer SJH, Transmembrane TNF-alpha, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn’s disease. Gastroenterology (2001) 121: 1242–5.
   Google Scholar
• Keane J, Gershon S, Wise RP et al, Tuberculosis associated with infliximab: tumor necrosis factor-alpha- neutralizing agents. NEJM (2001) 345: 1098–1104.
   PubMed Web of Science ®Google Scholar
• Peterson JR, Safety of TNF-alpha antagonists in patients with rheumatoid arthritis and chronic hepatitis C. Ann Rheum Dis (2002) 61: 38.
   Google Scholar
• Pritchard C, Etanercept and hepatitis C. J Clin Rheumatol (1999) 5: 179–180.
   PubMed Web of Science ®Google Scholar
• Ince A, Rusche W, Daud U et al, Etanercept in the treatment of rheumatoid arthritis patients with chronic hepatitis-C infection. Ann Rheum Dis (2002) 61.
   Google Scholar
• Zein NN, Etanercept Study Group. A phase II randomized, double blind, placebo controlled study of tumor necrosis factor anagonist (etanercept, Enbrel) as an adjuvant to interferon and ribavirin in naive patients with chronic hepatitis C. 53rd Annual Meeting of the American Association for the Study of Liver Diseases (2002) 101808(abstr).
   Google Scholar
• Neuman MG, Benhamou JP, Ibrahim A et al, Role of cytokines in the assessment of the severity of chro- nic hepatitis C and the prediction of response to therapy. Romanian Journal of Gastroenterology (2002) 11: 97–103.
   Google Scholar
• Neuman MG, Benhamou JP, Bourliere M et al, Serum tumor necrosis factor-alpha and transforming growth factor-beta levels in chronic hepatitis C patients are immunomodulated by therapy. Cytokine (2002) 17: 108–17.
   Google Scholar
• Neuman MG, Benhamou JP, Malkiewicz IM et al, Kinetics of serum cytokines reflect changes in the severity of chronic hepatitis C presenting minimal fibrosis. Journal of Viral Hepatitis (2002) 9: 134–40.
   PubMed Web of Science ®Google Scholar
• Neuman MG, Benhamou JP, Malkiewicz IM et al, Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis C. Clinical Biochemistry (2001) 34: 173–82.
   Google Scholar